Azathioprine
- Generic Name
- Azathioprine
- Brand Names
- Azasan, Imuran, Jayempi
- Drug Type
- Small Molecule
- Chemical Formula
- C9H7N7O2S
- CAS Number
- 446-86-6
- Unique Ingredient Identifier
- MRK240IY2L
- Background
Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index. Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transp...
- Indication
Azathioprine is indicated to treat rheumatoid arthritis and prevent renal transplant rejection.
- Associated Conditions
- Atopic Dermatitis, Crohn's Disease (CD), Immune Thrombocytopenia (ITP), Kidney Transplant Rejection, Lupus Nephritis, Multiple Sclerosis, Pericarditis, Psoriasis, Rheumatoid Arthritis, Uveitis
- Associated Therapies
- -
Comparison of Efficacy of Methotrexate and Azathioprine in Patients With Chronic Actinic Dermatitis: A Randomized Controlled Trial
- Conditions
- Interventions
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Pak Emirates Military Hospital
- Target Recruit Count
- 88
- Registration Number
- NCT06476366
- Locations
- 🇵🇰
Pak Emirates Military Hospital, Rawalpindi, Punjab, Pakistan
Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)
- Conditions
- Interventions
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Chinese SLE Treatment And Research Group
- Target Recruit Count
- 40
- Registration Number
- NCT05965284
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Monitoring of Azathioprine Metabolite Concentrations and Cytokine Levels in Neuromyelitis Optica Spectrum Disorder
- Conditions
- Interventions
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2023-06-09
- Target Recruit Count
- 63
- Registration Number
- NCT05896605
- Locations
- 🇨🇳
Qingmeng Huang, Nanning, Guangxi, China
HLADQA1*05 Genotype and the Efficacy of Treatment With Infliximab in Chinese Population Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2023-04-14
- Last Posted Date
- 2023-05-09
- Target Recruit Count
- 976
- Registration Number
- NCT05813860
Uterus Transplantation to Treat Infertility
- Conditions
- Interventions
- First Posted Date
- 2022-12-12
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 40
- Registration Number
- NCT05646992
- Locations
- 🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Azathioprine in MOGAD
- Conditions
- Interventions
- First Posted Date
- 2022-04-27
- Last Posted Date
- 2022-11-28
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 126
- Registration Number
- NCT05349006
- Locations
- 🇫🇷
Department of Neurology, Hôpital Caremeau, Nîmes, France
🇫🇷Department of Neurology, CHU de Rennes, Rennes, France
🇫🇷Department of Neurology, CHU of Lille, Hospital Roger Salengro, Lille, France
Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid
- Conditions
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 2
- Registration Number
- NCT05263505
- Locations
- 🇺🇸
Barnes Jewish Hospital / Washington University in St. Louis, Saint Louis, Missouri, United States
Clinical Study of Cord Blood Mononuclear Cells on Treatment of Hormone-resistant or Hormone-dependent Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- Shandong Qilu Stem Cells Engineering Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT04882683
- Locations
- 🇨🇳
The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Shandong, Shandong, China
Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR
- Conditions
- Interventions
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 80
- Registration Number
- NCT04773392
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
N-3 Polyunsaturated Fatty Acids Prevent Postoperative Recurrence of Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2021-02-21
- Target Recruit Count
- 236
- Registration Number
- NCT04761952
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.